Kevin Moulder
23Patents
4h-index
16Co-inventors
56Inventor score
Filing activity: Apr 8, 2005 → Nov 30, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7563443B2 | Monovalent anti-CD40L antibody polypeptides and compositions thereof | Chemistry; Metallurgy | 30 | Expired |
| US10752691B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US10745485B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US10738125B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 10 | Active |
| US7829096B2 | CD40L-specific monovalent polypeptides | Chemistry; Metallurgy | 1 | Active |
| US11236173B2 | CD38 antibody | Chemistry; Metallurgy | 1 | Active |
| US11542338B2 | CD38 modulating antibody | Chemistry; Metallurgy | 1 | Active |
| US7927596B2 | Methods of antagonizing binding of CD40 to CD40L with CD40L-specific monovalent polypeptides | Chemistry; Metallurgy | 1 | Active |
| US12343394B2 | CD38 modulating antibody agents | Chemistry; Metallurgy | 0 | Active |
| US12304964B2 | CD38 modulating antibody | Chemistry; Metallurgy | 0 | Active |
| US11879014B2 | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody | Chemistry; Metallurgy | 0 | Active |
| US8524236B2 | Methods of antagonizing the binding of CD40 to CD40L with CD40L-specific monovalent polypeptides in autoimmune individuals | Chemistry; Metallurgy | 0 | Active |
| US11697688B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11802161B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11814434B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11919960B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
| US11787866B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
| US11851494B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11873341B2 | Anti-CD25 for tumour specific cell depletion | Chemistry; Metallurgy | 0 | Active |
| US11780930B2 | CD38 modulating antibody | Chemistry; Metallurgy | 0 | Active |
| US11802160B2 | Anti-CD25 antibody agents | Chemistry; Metallurgy | 0 | Active |
| US12162949B2 | CD38 antibody | Chemistry; Metallurgy | 0 | Active |
| US12161717B2 | CD38 modulating antibody agents | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.